These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 11474784)

  • 1. HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein.
    Wang E; Casciano CN; Clement RP; Johnson WW
    Pharm Res; 2001 Jun; 18(6):800-6. PubMed ID: 11474784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport.
    Sakaeda T; Fujino H; Komoto C; Kakumoto M; Jin JS; Iwaki K; Nishiguchi K; Nakamura T; Okamura N; Okumura K
    Pharm Res; 2006 Mar; 23(3):506-12. PubMed ID: 16388406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HMG-CoA Reductase Inhibitors (Statins) and their Drug Interactions Involving CYP Enzymes, P-glycoprotein and OATP Transporters-An Overview.
    Balasubramanian R; Maideen NMP
    Curr Drug Metab; 2021; 22(5):328-341. PubMed ID: 33459228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors.
    Yang SH; Choi JS; Choi DH
    Pharmacology; 2011; 88(1-2):1-9. PubMed ID: 21709429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors.
    Lee CK; Choi JS; Choi DH
    Pharmacol Rep; 2015 Feb; 67(1):44-51. PubMed ID: 25560574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations.
    Prueksaritanont T; Ma B; Tang C; Meng Y; Assang C; Lu P; Reider PJ; Lin JH; Baillie TA
    Br J Clin Pharmacol; 1999 Mar; 47(3):291-8. PubMed ID: 10215754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.
    Williams D; Feely J
    Clin Pharmacokinet; 2002; 41(5):343-70. PubMed ID: 12036392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia.
    Naoumova RP; Marais AD; Mountney J; Firth JC; Rendell NB; Taylor GW; Thompson GR
    Atherosclerosis; 1996 Jan; 119(2):203-13. PubMed ID: 8808497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies.
    Pasha MK; Muzeeb S; Basha SJ; Shashikumar D; Mullangi R; Srinivas NR
    Biomed Chromatogr; 2006 Mar; 20(3):282-93. PubMed ID: 16143964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct effects of pravastatin, atorvastatin, and simvastatin on insulin secretion from a beta-cell line, MIN6 cells.
    Ishikawa M; Okajima F; Inoue N; Motomura K; Kato T; Takahashi A; Oikawa S; Yamada N; Shimano H
    J Atheroscler Thromb; 2006 Dec; 13(6):329-35. PubMed ID: 17192698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simvastatin and lovastatin, but not pravastatin, interact with MDR1.
    Sakaeda T; Takara K; Kakumoto M; Ohmoto N; Nakamura T; Iwaki K; Tanigawara Y; Okumura K
    J Pharm Pharmacol; 2002 Mar; 54(3):419-23. PubMed ID: 11902809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells.
    Mulhaupt F; Matter CM; Kwak BR; Pelli G; Veillard NR; Burger F; Graber P; Lüscher TF; Mach F
    Cardiovasc Res; 2003 Sep; 59(3):755-66. PubMed ID: 14499877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin.
    Hochman JH; Pudvah N; Qiu J; Yamazaki M; Tang C; Lin JH; Prueksaritanont T
    Pharm Res; 2004 Sep; 21(9):1686-91. PubMed ID: 15497697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HMG-CoA reductase activity in human liver microsomes: comparative inhibition by statins.
    Dansette PM; Jaoen M; Pons C
    Exp Toxicol Pathol; 2000 May; 52(2):145-8. PubMed ID: 10965989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion.
    Turner NA; Midgley L; O'Regan DJ; Porter KE
    J Cardiovasc Pharmacol; 2007 Oct; 50(4):458-61. PubMed ID: 18049315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells.
    Morikawa S; Umetani M; Nakagawa S; Yamazaki H; Suganami H; Inoue K; Kitahara M; Hamakubo T; Kodama T; Saito Y
    J Atheroscler Thromb; 2000; 7(3):138-44. PubMed ID: 11480454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential interactions between statins and P-glycoprotein: implications for exploiting statins as anticancer agents.
    Goard CA; Mather RG; Vinepal B; Clendening JW; Martirosyan A; Boutros PC; Sharom FJ; Penn LZ
    Int J Cancer; 2010 Dec; 127(12):2936-48. PubMed ID: 21351272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of pravastatin, simvastatin, and atorvastatin on Ca2+ release and vascular reactivity.
    Tesfamariam B; Frohlich BH; Gregg RE
    J Cardiovasc Pharmacol; 1999 Jul; 34(1):95-101. PubMed ID: 10413074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New insights into the pharmacodynamic and pharmacokinetic properties of statins.
    Corsini A; Bellosta S; Baetta R; Fumagalli R; Paoletti R; Bernini F
    Pharmacol Ther; 1999 Dec; 84(3):413-28. PubMed ID: 10665838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.